Information on NKTCL1
Basic details
Name: NK/T-cell lymphomas 1 | Acronym: NKTCL1
Alt. names: peripheral T-cell lymphomas
Gene: STAT3 | MOI: Somatic | Mechanism of action: Gain of Function
No. of cases in DB: 9 | First reported in: 2013
Last updated on: 2023-04-24 15:58:51 by Xiao P. Peng
Description
Somatic activating mutations in STAT3 have been found in people with anaplastic large T-cell lymphomas or not-specified peripheral T-cell lymphomas (PMID:23563237), NK/T-cell lymphomas (PMID:25586472) or peripheral gamma-delta-T-cell derived lymphomas (PMID:25586472).
Management
Description of management option has not been reviewed yet.
9 reported cases added to GenIA
| SubjectID | Sex | Fam.ID | AD | AFM | Validity | Country | Population | Reference & Pub.code |
|---|---|---|---|---|---|---|---|---|
104329 |
U | 215468 | Definitive | PMID:25586472 [S614R] | ||||
| 104330 |
U | 215469 | Definitive | PMID:25586472 [D661Y] | ||||
| 104331 |
U | 215470 | Definitive | PMID:25586472 [A702T] | ||||
| 107122 |
U | 216341 | Definitive | PMID:25586472 [G618R] | ||||
| 107123 |
U | 216342 | Definitive | PMID:25586472 [Y640F] | ||||
| 107134 |
M | 216353 | 73 | Definitive | U.S.A. | PMID:23563237 [ALCL-1] | ||
| 107135 |
M | 216354 | 74 | Definitive | U.S.A. | PMID:23563237 [ALCL-2] | ||
| 107136 |
M | 216355 | 66 | Definitive | U.S.A. | PMID:23563237 [PTCL-1] | ||
| 107137 |
F | 216356 | 33 | Definitive | U.S.A. | PMID:23563237 [PTCL-2] |
AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).
Summary of clinical findings
[Considering only Definitive and Possible cases]
| Rank | Clinical term | Present | Absent | Unreported |
|---|---|---|---|---|
| 1 | Non-Hodgkin lymphoma |
9 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 2 | NK/T-cell lymphoma |
3 (33.3%) | 0 (0.0%) | 6 (66.7%) |
| 3 | gamma-delta-T-cell derived lymphoma |
2 (22.2%) | 0 (0.0%) | 7 (77.8%) |
| 4 | T-cell lymphoma |
2 (22.2%) | 0 (0.0%) | 7 (77.8%) |
| 5 | Anaplastic large-cell lymphoma |
2 (22.2%) | 0 (0.0%) | 7 (77.8%) |
Summary of treatment outcomes
[Considering only Definitive and Possible cases]
| Treatment ⓘ | Responses & clinical indications |
|---|